Vedanthan Rajesh, Kamano Jemima H, Lee Hana, Andama Benjamin, Bloomfield Gerald S, DeLong Allison K, Edelman David, Finkelstein Eric A, Hogan Joseph W, Horowitz Carol R, Manyara Simon, Menya Diana, Naanyu Violet, Pastakia Sonak D, Valente Thomas W, Wanyonyi Cleophas C, Fuster Valentin
Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Moi University College of Health Sciences, School of Medicine, Eldoret, Kenya; Academic Model Providing Access to Healthcare, Eldoret, Kenya.
Am Heart J. 2017 Jun;188:175-185. doi: 10.1016/j.ahj.2017.03.012. Epub 2017 Mar 23.
Cardiovascular disease (CVD) is the leading cause of mortality worldwide, with >80% of CVD deaths occurring in low and middle income countries (LMICs). Diabetes mellitus and pre-diabetes are risk factors for CVD, and CVD is the major cause of morbidity and mortality among individuals with DM. There is a critical period now during which reducing CVD risk among individuals with diabetes and pre-diabetes may have a major impact. Cost-effective, culturally appropriate, and context-specific approaches are required. Two promising strategies to improve health outcomes are group medical visits and microfinance.
METHODS/DESIGN: This study tests whether group medical visits integrated into microfinance groups are effective and cost-effective in reducing CVD risk among individuals with diabetes or at increased risk for diabetes in western Kenya. An initial phase of qualitative inquiry will assess contextual factors, facilitators, and barriers that may impact integration of group medical visits and microfinance for CVD risk reduction. Subsequently, we will conduct a four-arm cluster randomized trial comparing: (1) usual clinical care, (2) usual clinical care plus microfinance groups only, (3) group medical visits only, and (4) group medical visits integrated into microfinance groups. The primary outcome measure will be 1-year change in systolic blood pressure, and a key secondary outcome measure is 1-year change in overall CVD risk as measured by the QRISK2 score. We will conduct mediation analysis to evaluate the influence of changes in social network characteristics on intervention outcomes, as well as moderation analysis to evaluate the influence of baseline social network characteristics on effectiveness of the interventions. Cost-effectiveness analysis will be conducted in terms of cost per unit change in systolic blood pressure, percent change in CVD risk score, and per disability-adjusted life year saved.
This study will provide evidence regarding effectiveness and cost-effectiveness of interventions to reduce CVD risk. We aim to produce generalizable methods and results that can provide a model for adoption in low-resource settings worldwide.
心血管疾病(CVD)是全球主要死因,超过80%的心血管疾病死亡发生在低收入和中等收入国家(LMICs)。糖尿病和糖尿病前期是心血管疾病的危险因素,而心血管疾病是糖尿病患者发病和死亡的主要原因。目前存在一个关键时期,在此期间降低糖尿病和糖尿病前期患者的心血管疾病风险可能会产生重大影响。需要采用具有成本效益、适合文化背景且因地制宜的方法。两种有前景的改善健康结果的策略是团体医疗就诊和小额融资。
方法/设计:本研究测试融入小额融资团体的团体医疗就诊在降低肯尼亚西部糖尿病患者或糖尿病风险增加者的心血管疾病风险方面是否有效且具有成本效益。定性探究的初始阶段将评估可能影响团体医疗就诊与小额融资相结合以降低心血管疾病风险的背景因素、促进因素和障碍。随后,我们将进行一项四臂整群随机试验,比较:(1)常规临床护理,(2)仅常规临床护理加小额融资团体,(3)仅团体医疗就诊,以及(4)融入小额融资团体的团体医疗就诊。主要结局指标将是收缩压的1年变化,一个关键的次要结局指标是通过QRISK2评分衡量的总体心血管疾病风险的1年变化。我们将进行中介分析以评估社交网络特征变化对干预结果的影响,以及调节分析以评估基线社交网络特征对干预效果的影响。将根据收缩压每单位变化的成本、心血管疾病风险评分的百分比变化以及每挽救的残疾调整生命年进行成本效益分析。
本研究将提供关于降低心血管疾病风险干预措施的有效性和成本效益的证据。我们旨在产生可推广的方法和结果,为全球资源匮乏地区的采用提供一个模型。